Kornimate/medical-research-clean huggingface dataset:
the effect of intravenous magnesium sulfate on intraocular pressure following tracheal intubation

Conditions: Increased Intra Ocular Pressure (IOP)

Summary: the aim of this study is to assess the effect of preoperatively administered intra venous magnesium sulfate in attenuating pressure response to laryngoscopy and endotracheal intubation in adult patients scheduled for elective non ocular surgery


Eligibility criteria:
inclusion criteria: * 18 to 38 years old * asa i * scheduled for elective ent ambulatory surgeries under general anesthesia exclusion criteria: * specific major hepatic, renal and cardio-vascular disease * known to have allergic reaction to magnesium sulphate or other drugs , -hypermagnesemia * hypocalcemia * anuria * heart block * pregnancy * any degree of renal insufficiency * digitalised patients * positive history of glaucoma or intra ocular hypertension * refused to participate

Keywords: iop ophthalmic anesthesia magnesium sulfate
randomized trial comparing prediction accuracy of two swept source optical coherence tomography biometers

Conditions: Cataract

Summary: to assess if the alcon argos biometer utilizing the barrett universal ii formula for iol calculations can give a non-inferior outcome when compared to the zeiss iol master 700 utilizing the (pca) with the barrett universal ii (tk) formula, when comparing the (mean absolute prediction error of the predicted target spherical equivalencies).


Eligibility criteria:
inclusion criteria: * age: 50-85 years old * clinically significant cataracts that interfere with daily activities * patient is able to understand and able to consent to informed consent * patient is able to come to all postoperative visits and agrees to follow up at 30 days -2/+14 days * patient undergoing cataract surgery, with implantation of the alcon sn60wf lens in the capsular bag. exclusion criteria: * axial length \ 26.00 * corneal astigmatism \> +1.00 diopters * ccts: \ 600 * prior refractive surgery: rk, prk, lasik, intacts * history of contact lens use: soft lenses within 2 months of surgery, rgp within 60 months of surgery * corneal disease: keratoconus, corneal dystrophies, any prior corneal surgery, prior infections * retinal disease: macular pathology, cscr, cme, macular degeneration, drusen, retinal detachment, tppv, sb, prior ivt, prior prp or focal laser, diabetic retinopathy * history of uveitis * poag: undergoing any concomitant migs procedure- istent, omni, itrack, hydrus, etc * enrollment in any prior clinical trial within 2 years * systemic disease that in the investigator's opinion may affect outcome * currently pregnant or breastfeeding * severe dry eye * tear osmolarity \> 320mosms/l (moderate) * any surgical complication(s) * iol implanted outside of the capsular bag /capsular damage /weakness /ctr placement
ceftolozane-tazobactam for directed treatment of pseudomonas aeruginosa bacteremia and pneumonia in patients with hematological malignancies and hematopoietic stem cell transplantation

Conditions: Pseudomonas Aeruginosa; Pneumonia; Hematologic Malignancy

Summary: this is an open-label study, where participants will be given ceftolozane-tazobactam as the primary treatment for pseudomonas aeruginosa infections. open-label means both the investigator and the participant will known what drug will be given. participants will be followed for approximately 60 days. ceftolozane-tazobactam is approved by the food and drug administration (fda) for treatment of serious bacterial infection and the investigator hypothesizes that ceftolozane/tazobactam may be effective as the primary antibiotic treatment for pseudomonas aeruginosa infections.


Eligibility criteria:
inclusion criteria: * at least 18 years old * presence of hematologic malignancy or hematopoietic stem cell transplantation * identification of pseudomonas aeruginosa by rapid molecular diagnostic assay from a blood culture or from a respiratory sample in the setting of radiologically documented pneumonia and clinical symptoms compatible with pneumonia. exclusion criteria: * anaphylactic hypersensitivity or allergic reaction to cephalosporins * participants with expected mortality within 48 hours * hemodialysis or continuous renal replacement therapy, or creatinine clearance \<15 ml/min * prior non-study anti-pseudomonal therapy for \>72 hours * history of a strain of pseudomonas aeruginosa with mic \>4 microgram/ml to ceftolozane/tazobactam * polymicrobial aerobic gram-negative infection as determined by id research team patients who completed this study and subsequently experience a separate, recurrent pseudomonas aeruginosa infection, may be re-enrolled into this study if all eligibility criteria are met.

Keywords: pseudomonas aeruginosa pneumonia hematologic malignancy ceftolozane-tazobactam zerbaxa
effect of electronic cigarettes on platelets, endothelium and inflammation

Conditions: Smoking

Summary: the primary purpose of this study is to evaluate the acute effects of electronic cigarette (e-cigarette) smoking on measurable biomarkers of platelet function, vascular endothelial function and inflammation in healthy active smokers. 10 healthy subjects, smokers, with no other medical conditions will be included in this study and measurements will be obtained at baseline and after smoking an e-cigarette. the study will contribute to the understanding of the effects of e-cigarettes on cardiovascular physiology, specifically establishing if the use of e-cigarettes increases platelet aggregation and platelet activation when compared to baseline in healthy active smokers, if the use of e-cigarettes decreases brachial artery flow-mediated dilation compared to baseline in healthy active smokers, and to determine the association between biomarkers of inflammation, platelet function, and vascular endothelial function before and after use of e-cigarettes.


Eligibility criteria:
inclusion criteria: * adult english speaking subjects able and willing to provide written informed consent * active tobacco cigarette smoker * history of active smoking tobacco cigarettes for 3-10 years (at least 10 cigarettes per day). the rational for inclusion of active smokers is based on prior data showing that most e-cigarette users have smoked moderate to high amount of tobacco cigarettes in the past * no other use of alternative tobacco or nicotine products * no history of hypertension, diabetes, cardiovascular disease, stroke, peripheral arterial disease, asthma or other chronic lung disease. exclusion criteria: * use of aspirin, clopidogrel, prasugrel, ticagrelor, warfarin, statins, colchicine, nitrates, steroids, fish oil, omega-3 fatty acids, or any other anti-inflammatory, antithrombotic or anticoagulant agent in the last week * history of adverse reactions to e-cigarettes

Keywords: alternative tobacco products (atps) electronic cigarettes
the effects of glucose/ischemic preconditioning on reperfusion injury in deceased-donor liver transplantation

Conditions: Liver Transplantation

Summary: standard liver retrieval procedures for transplantation from a deceased donor inevitably result in a "reperfusion injury" to the liver tissue. the purpose of this research study is to find out whether treatment of the liver with a "preconditioning" protocol before its removal from the donor will help reduce any of this injury. the "preconditioning" treatment being tested has two components. firstly, a solution of glucose+insulin is infused and secondly, blood flow to the liver is stopped briefly (10 minutes) and then resumed. both strategies, individually, have been shown to reduce liver tissue injury in human studies. we hypothesize that combining both strategies will have a clinical benefit to patients and will improve liver function following transplant.

liver transplantation is the only chance of cure for patients with end-stage liver disease. unfortunately, standard organ preservation results in an ischemic-reperfusion injury (iri) at the time of graft implantation. novel strategies have been proposed to decrease reperfusion injury and improve graft function. this study will be the first to combine both strategies in a randomized, prospective trial. the intervention will occur during the retrieval surgery prior to cold preservation. briefly, a glucose and insulin solution will be infused via the mesenteric vein at a controlled rate. immediately prior to cross-clamping, blood supply to the liver will be restricted for 10 minutes and then resumed for 10 minutes before beginning cold preservation. all remaining surgical procedures, including the recipient surgery, will be performed by standard techniques. the liver recipient does not directly receive any intervention during this study.

Eligibility criteria:
inclusion criteria: * recipient 18 years of age or older * recipient with chronic end-stage liver disease * deceased donor liver transplant * recipient capable of providing written informed consent * whole organ graft from donors aged 60 years or older exclusion criteria: * fulminant liver failure * objection by any other member of the retrieval team * split-liver grafts * donor that has received total parenteral nutrition within 24hr of organ retrieval donors from whom the pancreas and/or small bowel are also being retrieved

Keywords: liver disease transplantation
assessment of pelvic floor muscle training using modern conservative methods in the therapy of stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the eim is to evaluate the clinical effectiveness of pelvic floor muscle training (pfmt) in conservative therapy in women with objective, urodynamic stress urinary incontinence using home exercise training with the medical vaginal device versus standard pelvic floor muscle training-exercises

the first group were using vaginal device - commercial name aniball inco®, which is controlled by the czech state institute of drug control which is registered by the european medical device nomenclature (emdn) with unique device identifier - device identifier (udi-di) - 859418371002la the second group - the education was provided by certified physiotherapist trained in pelvic floor disroder

Eligibility criteria:
inclusion criteria: stress urinary incontinence exclusion criteria: age under 18, age over 80, isd (intrinsic sphincter deficiency), descent of the pelvic organs according to pop-q ≥ 2 (stage), urgent incontinence ruled out using a questionnaire (oab v8 - overactive bladder \< 7a ppius - patient perception of intensity and urgency scale ≤ 1), overactive bladder (oab) with the use of anticholinergics, pregnant women and women up to 6 months after childbirth, active pelvic cancer, degenerative neurological or myofascial disease, reduced cognitive function that does not allow understanding the principles of the study, impossibility of contraction mm.levatores ani., recurrent vaginal inflammation, atrophic vulvovaginitis, irregular bleeding, contraindications listed by the manufacturer of the medical device aniball inco.

Keywords: stress urinary incontinence physiotherapy of pelvic floor conservative treatment
screening for chromosomal microarrangements by cgh-array in developmental anomalies of the skin suggestive of mosaicism.

Conditions: Malformations With Skin Manifestations Suggesting Mosaicism

Summary: the principal result expected is the discovery of inframicroscopic chromosomal rearrangements in regions of the genome not yet known to be involved, or mutations in known candidate genes; the identification of such a mosaic rearrangement in an affected infant would lead to improved genetic counselling. indeed, as this mosaicism is a consequence of a genetic event occurring at an early stage of embryogenesis, it would be possible to confirm the sporadic nature of the observed disorder and therefore to predict a very low or even negligible risk of recurrence for the couple concerned. for the affected infant, the risk for his/her own offspring will be assessed according to the nature of the genetic anomaly discovered. for medical practice, investigators hope that this study will lead to a clearer definition of the screening modalities for mosaicism in the disorders concerned. in particular, they hope to determine whether or not it is possible to dispense with a skin biopsy, which is more invasive than a blood sample.


Eligibility criteria:
inclusion criteria: * persons who have provided written informed consent * lower age limit: infant born at more than 37 wa * sporadic disorder * patients presenting at least two skin criteria, or one skin criterion and one non-skin criterion * skin criteria: 1- extensive epidermal or sebaceous naevus, 2- extensive "segmental" haemangioma, 3- flat angioma or extensive complex vascular malformation, 4-pigmentary disorders with patterns suggesting mosaicism (blaschko lines) * non-skin criteria: cerebral, ocular, cardiac or genito-urinary malformation, asymmetric body, segmental hypertrophy of a limb, spinal dysraphism (only when associated with haemangioma) exclusion criteria: * persons not covered by the national health insurance scheme * mendelian disorders: cm-avm syndrome, glomangiomatosis, cowden or bannayan syndrome, type 1 neurofibromatosis, incontinentia pigmenti, child syndrome, happle-type chondrodysplasia punctata * mendelian mosaic disorders: epidermal or epidermolytic, comedo or dyskeratotic nevus. * family history of one of these disorders * suspicion or an autosomal dominant disease * patient and/or parent under guardianship or ward of court
genetic, neurophysiological and psychological risk factors for neuropathic pain

Conditions: Surgery

Summary: the objective of these cohorts is to detect potential genetic, neurophysiological psychological and cognitive risk factors for the development of chronic postsurgical pain including neuropathic pain.

this new study will enroll patients undergoing mastectomy or thoracotomy for cancer. they will be three cohorts : * one prospective cohort constituted of women undergoing breast surgery in rené huguenin hospital (saint cloud) and followed for up to one year after surgery. * another cross sectional cohort constituted of patient association (seintinelle) including women operated up to 2 years previously from breast surgery. * one prospective cohort constituted of women or men undergoing thoracotomy in foch hospital (suresnes) and followed for up to one year after surgery. the main objectives of these cohorts will be to detect potential genetic, neurophysiological, psychological and cognitive risk factors for the development of chronic postsurgical neuropathic pain. these patients will questioned about demographics, age, sex, body mass index. a large neuropsychological and psychological battery of tests will be conducted. sensory function will assessed using quantitative sensory testing. biological samples will analyse potential genetic factors in the development of neuropathic pain after surgery. conditioned pain modulation, threshold tracking and quantitative sensory testing will also be assessed in subgroup of patients. the prospective cohort will be assessed before surgery then 3, 6 and 12 months after surgery. the cross sectional cohort will be assessed during one to two visits in hospital.

Eligibility criteria:
inclusion criteria: * patients undergoing surgery for breast cancer or thoracotomy for lung cancer followed during the course of the study or patients from the french cohort seintinelle already operated from breast surgery over the past 2 years. exclusion criteria : * patients are not included if they have clinically significant or unstable psychiatric or somatic conditions (e.g. major depression, psychosis, uncontrolled diabetes mellitus or hypertension, neurological disorders, immune disease, body mass index \> 45), past or present substance abuse or any cognitive deterioration based on past medical history, semi-structured interview and lack of completion or full understanding of questionnaires. * bilateral mastectomy (for women undergoing breast surgery) * presence of pain before surgery
study of remote ischemic postconditioning

Conditions: Ischemia; Bypass Complications

Summary: cardiac surgery is associated with cardiac and cerebral injury because of ischemia/reperfusion in approximately one third of cases. ischemic preconditioning (ipc), have been shown to reduce the extent of myocardial infarction (mi). as another ischemic conditioning, remote ischemic postconditioning, limits mi size in animal models. the purpose of this study is to evaluate the cardiac and cerebral protective effect of remote ischemic postconditioning in children undergoing cardiac surgery, as a single-center, randomized controlled trial.

cardiac surgery is associated with troponin release because of ischemia/reperfusion injury in approximately one third of cases. and i/r injury may also induce cerebral insult, even postoperative cognitive dysfunction (pocd).transient sublethal episodes of ischemia before a prolonged ischemia/reperfusion injury, known as ischemic preconditioning (ipc), have been shown to reduce the extent of myocardial infarction (mi).and remote ischemic postconditioning(ripoc), as another ischemic condition, limits mi size in animal models. however, there are limited outcome to demonstrate protection from ripoc during cardiac surgery. the purpose of this study is to investigate the cardiac and cerebral protective effect of remote ischemic postconditioning , as a single-center, randomized controlled trial.

Eligibility criteria:
inclusion criteria: * all children aged from 0 to 12 who are undergoing open congenital cardiac surgery. exclusion criteria: * simple atrial septal defect * bidirectional cavopulmonary shunt undergoing fontan completion * chromosomal defects * airway or parenchymal lung disease * immunodeficiency * blood disorder
an investigation on the effect of candesartan on early diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: it is well understood that hypertension, dyslipidemia, and diabetes mellitus are the major risks of chronic kidney disease. current guidelines recommend screening kidney estimated glomerular filtration function with serum creatinine. but it is not the utmost effective method and the gfr would be underestimated. since good correlation was noticed between serum creatinine and chronic kidney disease, urinary microalbumin levels is better for patients with risks of chronic kidney diseases. with adequate and early education, or antihypertensive agents with angiotensin converting enzyme inhibitors (acei) or angiotensin ii receptor blockers (arb), all could alleviate renal function deterioration and the severity of proteinuria. as a result, high sensitive methods is urgent and needed for early screening and diseases following up under medication with acei and arb in chronic kidney disease patients. in this project, the investigators are going to include the patients with typy ii diabetes mellitus combining with hypertension who are treated with antihypertensive agents. such volunteers will be treated with candesartan 8-16mg/ day and maintain systolic blood pressure \<130 mm/hg, diastolic blood pressure \< 80 mm/ hg as the goal. therefore, this project would make effort on correlation with urinary microalbumin and other biomarkers changes under candesartan treatment- one of arb medication for 12 weeks, and further exploration of new biomarkers that may be related to renal parenchymal injuries.


Eligibility criteria:
inclusion criteria: 1. type ii diabetic disease with hypertension (bp: systolic 140-160 mm/hg, diastolic 80-100 mm/hg) for 8 weeks. 2. hba1c\< 8.0% 3. cre. \<1.5 g/dl and egfr: 89 - 30 ml/min/1.73 m2 exclusion criteria: 1. pregnancy 2. during the observation, bp: systolic \>160 mm/hg, diastolic \>100 mm/hg).

Keywords: hypertension primary disease
jasper implementation in nfld

Conditions: Autism Spectrum Disorder

Summary: this study will focus on examining the supports required to enable community senior jasper trainers to support the training and development of junior interventionists throughout the province of newfoundland and labrador, canada. the study will examine the training and supports delivered by senior trainers to help junior interventionists provide a targeted social communication intervention (jasper: joint attention, symbolic play, engagement, and regulation) with children with autism spectrum disorder (asd). children's engagement, play, and social communication outcomes will be examined as well as the influence of junior interventionists' intervention implementation on children's outcomes. further, the study will examine the supports required to help junior interventionists who demonstrate slower gains in implementation fidelity after the first three months of standard support. interventionists who are slow to gain implementation fidelity will be randomized to either (a) enhanced feedback plus peer support or (b) enhanced feedback plus intensive refresher course.

the proposed study is an adaptive intervention trial that will focus on tailoring supports for new jasper interventionists. coaching and training supports will be provided by local senior jasper trainers will support the development of new interventionists. based on the interventionist's individual response to the coaching/training supports, a change in support may be provided at a priori time points including end of month 1 (training case) if at least 70% fidelity is not reached, and at end of month 4 (midpoint of first child cohort), at least 90% fidelity is not reached.

Eligibility criteria:
inclusion criteria: * children: must be 2.0-8.11 years of age; must meet the scoring benchmark for "autism" or "autism spectrum disorder" on the ados-2; has not previously received jasper intervention in the province * interventionists: work as an interventionist for the government of newfoundland and labrador; minimum educational requirement is a bachelor's degree or master's degree in psychology or a related field * senior jasper trainers: - have been trained previously in jasper; work as a senior trainer for the government of newfoundland and labrador; minimum educational requirement is a master's degree in a related field (e.g., speech and language pathology, occupational therapy, developmental psychology). exclusion criteria: * children: child is below 2.0 years of age or above 8.11 years of age; child does not meet the benchmark for autism or autism spectrum disorder on the ados-2; child has received jasper intervention prior to this study * interventionists: not employees of the government of newfoundland and labrador; does not hold a bachelor's degree in a related field * senior trainers: no prior jasper training; not employees of the government of newfoundland and labrador; does not hold a master's degree in a related field

Keywords: training intervention social communication play